To test this, K562 cells infected with the dual-CRISPR library targeting UCEs were exposed to the tyrosine kinase inhibitor imatinib that targets the BCR-ABL fusion kinase in K562 cells and other related chronic myeloid leukaemias. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.